MICAFUNGIN - THE NEWEST ECHINOCANDIN

被引：11
作者：
Temesgen, Zelalem [1 ]
Barreto, Jason N. [1 ]
Vento, Sandro [2 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Annunziata Hosp, Cosenza, Italy
来源：
DRUGS OF TODAY | 2009年 / 45卷 / 06期
关键词：
LIPOSOMAL AMPHOTERICIN-B; LIPOPEPTIDE ANTIFUNGAL AGENT; IN-VITRO ACTIVITY; NERVOUS-SYSTEM ASPERGILLOSIS; INVASIVE FUNGAL-INFECTIONS; STEM-CELL TRANSPLANTATION; DEEP-SEATED MYCOSIS; DOUBLE-BLIND TRIAL; DISSEMINATED CANDIDIASIS; ESOPHAGEAL CANDIDIASIS;
D O I：
10.1358/dot.2009.45.6.1378277
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is generally well tolerated with few significant adverse effects.
引用
收藏
页码：469 / 478
页数：10
相关论文
共 51 条
[1]   Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. [J].
Arikan, S ;
Yurdakul, P ;
Hascelik, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2640-2643
[2]  
*AST PHARM US INC, 2007, MYC PACK INS
[3]   From natural products to clinically useful antifungals [J].
Barrett, D .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3) :224-233
[4]   Changing face of health-care associated fungal infections [J].
Bille, J ;
Marchetti, O ;
Calandra, T .
CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (04) :314-319
[5]   Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis [J].
Chandrasekar, PH ;
Cutright, JL ;
Manavathu, EK .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (10) :925-928
[6]   Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis [J].
Clemons, Karl V. ;
Parmar, Rachana ;
Martinez, Marife ;
Stevens, David A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) :466-469
[7]   Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis [J].
Clemons, KV ;
Stevens, DA .
MEDICAL MYCOLOGY, 2006, 44 (01) :69-73
[8]   Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis [J].
Clemons, KV ;
Espiritu, M ;
Parmar, R ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :4867-4875
[9]   A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients [J].
de Wet, N ;
Llanos-Cuentas, A ;
Suleiman, J ;
Baraldi, E ;
Krantz, EF ;
Della Negra, M ;
Diekmann-Berndt, H .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :842-849
[10]   A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis [J].
de Wet, NTE ;
Bester, AJ ;
Viljoen, JJ ;
Filho, F ;
Suleiman, JM ;
Ticona, E ;
Llanos, EA ;
Fisco, C ;
Lau, W ;
Buell, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :899-907
123456